Schrodinger, Inc. Common Stock
SDGRSchrödinger, Inc. (SDGR) is a software and services company specializing in advanced computational solutions for drug discovery and materials science. It develops physics-based modeling platforms that accelerate the development of new pharmaceuticals and materials by providing precise simulations of molecular interactions. Schrödinger aims to transform research and development in life sciences and chemistry through its cutting-edge computational tools.
Company News
The generative AI in drug discovery market is experiencing significant expansion, growing from $0.25 billion in 2025 to $0.33 billion in 2026, with projections to reach $0.86 billion by 2030 at a 27% CAGR. Key drivers include rising drug development costs, computational chemistry advancements, increased biological datasets, and strategic collabor...
The AI drug discovery field is shifting focus from building the most powerful models to establishing trustworthy, connected biological data foundations. MindWalk Holdings (HYFT) has positioned itself as a leader in this 'context layer' approach with its ReefIQ and LensAI platforms, reporting 52% YoY revenue growth and its first recurring platform...
Recursion Pharmaceuticals and Schrödinger represent different approaches to AI-driven drug discovery—one biotech-focused with clinical-stage programs, the other software-first with recurring revenue. While both show strong growth (26.9% and 23.3% respectively), Recursion trades at a premium valuation (26.1x P/S) with significant losses and no ...
With stabilizing interest rates and increased FDA activity, three biotech companies stand out: Schrödinger combines AI-driven drug discovery with established software revenue ($256M in 2025); Sarepta generates nearly $2B in annual product revenue from gene therapy despite ongoing safety concerns around Elevidys; and NRX Pharmaceuticals, a specul...
The biosimulation market is experiencing robust growth, projected to expand from USD 4.7 billion in 2025 to USD 20 billion by 2034 at a CAGR of ~17%. Growth is driven by increasing adoption of model-informed drug development (MIDD), rising complexity of modern therapeutics, regulatory support from FDA and EMA, and the shift toward virtual clinica...
